PPA
BCRX icon

Parametric Portfolio Associates’s BioCryst Pharmaceuticals BCRX Stock Holding History

Parametric Portfolio Associates’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		$3.23M Buy
198,832
+70,189
+55% +$1.13M ﹤0.01% 2138
2021
Q4 		$1.78M Sell
128,643
-100,413
-44% -$1.33M ﹤0.01% 2503
2021
Q3 		$3.29M Buy
229,056
+9,042
+4% +$143K ﹤0.01% 2123
2021
Q2 		$3.48M Buy
220,014
+118,825
+117% +$1.61M ﹤0.01% 2111
2021
Q1 		$1.03M Buy
101,189
+16,655
+20% +$172K ﹤0.01% 3154
2020
Q4 		$630K Buy
84,534
+189
+0.2% +$974 ﹤0.01% 3274
2020
Q3 		$290K Sell
84,345
-457,784
-84% -$1.96M ﹤0.01% 3499
2020
Q2 		$2.58M Buy
542,129
+492,761
+998% +$1.97M ﹤0.01% 2335
2020
Q1 		$99K Buy
49,368
+17,849
+57% +$49.1K ﹤0.01% 3733
2019
Q4 		$109K Sell
31,519
-25,099
-44% -$63.1K ﹤0.01% 3849
2019
Q3 		$162K Buy
56,618
+39,963
+240% +$124K ﹤0.01% 3755
2019
Q2 		$63K Sell
16,655
-112,651
-87% -$678K ﹤0.01% 3893
2019
Q1 		$1.05M Buy
129,306
+13,196
+11% +$113K ﹤0.01% 3005
2018
Q4 		$937K Buy
+116,110
New +$903K ﹤0.01% 3020
2018
Q3 		– Sell
-14,284
Closed -$82K – 3940
2018
Q2 		$82K Buy
14,284
+1,407
+11% +$7.75K ﹤0.01% 3822
2018
Q1 		$61K Buy
12,877
+1,157
+10% +$5.95K ﹤0.01% 3894
2017
Q4 		$58K Buy
11,720
+648
+6% +$3.14K ﹤0.01% 3859
2017
Q3 		$58K Buy
+11,072
New +$56.7K ﹤0.01% 3986
2014
Q4 		– Sell
-14,960
Closed -$146K – 3982
2014
Q3 		$146K Buy
+14,960
New +$183K ﹤0.01% 3676

Other funds holding BCRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
PAMS
Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return
RM
RP Management New York $139M AUM 37.98% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Parametric Portfolio Associates's BCRX Position: Q1 2022 in Review

Parametric Portfolio Associates increased its BioCryst Pharmaceuticals (BCRX) stake by 55% in Q1 2022, buying an estimated $1.13M and bringing the position to 198,832 shares worth $3.23M. The position accounts for ﹤0.01% of the portfolio, ranked #2138.

Parametric Portfolio Associates first reported a position in BCRX in Q3 2014 and has held it in 19 quarters since. The position peaked at $3.48M in Q2 2021. 233 funds tracked by Wall St. Rank hold BCRX as of Q1 2022.

  • Parametric Portfolio Associates held 198,832 shares of BioCryst Pharmaceuticals worth $3.23M as of Q1 2022.
  • Parametric Portfolio Associates bought 70,189 BioCryst Pharmaceuticals shares in Q1 2022, an estimated $1.13M.
  • BioCryst Pharmaceuticals made up ﹤0.01% of Parametric Portfolio Associates's portfolio in Q1 2022, its #2138 holding.
  • Parametric Portfolio Associates first reported a position in BioCryst Pharmaceuticals in Q3 2014 and has held it in 19 quarters since.
  • Parametric Portfolio Associates's BioCryst Pharmaceuticals position peaked at $3.48M in Q2 2021.
  • 233 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q1 2022.

Based on Parametric Portfolio Associates's 13F filing for Q1 2022, filed 16 May 2022.